ASCO 2016: More Excitement About Daratumumab (Darzalex®) and Tremendous Interest in Value and Costs

As usual, far fewer myeloma-related abstracts will be presented at next month's annual meeting of the American Society of Clinical Oncology (ASCO) than are presented at the annual meeting of the American Society of Hematology (ASH) each December. But, writes IMF Chairman Dr. Brian Durie in his blog this week, the results of the Phase III CASTOR study have created some excitement, and the subjects of “cost” and “value” in cancer treatment are definitely in the air! To read Dr. Durie's blog, click HERE.
Source: International Myeloma Foundation - Category: Hematology Source Type: news